Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.
Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O. Papeix C, et al. Among authors: de seze j. Mult Scler. 2007 Mar;13(2):256-9. doi: 10.1177/1352458506070732. Epub 2007 Jan 29. Mult Scler. 2007. PMID: 17439893
Neuromyelitis optica and non organ-specific autoimmunity.
Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Pittock SJ, et al. Among authors: de seze j. Arch Neurol. 2008 Jan;65(1):78-83. doi: 10.1001/archneurol.2007.17. Arch Neurol. 2008. PMID: 18195142
Cognitive functions in neuromyelitis optica.
Blanc F, Zéphir H, Lebrun C, Labauge P, Castelnovo G, Fleury M, Sellal F, Tranchant C, Dujardin K, Vermersch P, de Seze J. Blanc F, et al. Among authors: de seze j. Arch Neurol. 2008 Jan;65(1):84-8. doi: 10.1001/archneurol.2007.16. Arch Neurol. 2008. PMID: 18195143
Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Scott TF, et al. Among authors: de seze j. Neurology. 2011 Dec 13;77(24):2128-34. doi: 10.1212/WNL.0b013e31823dc535. Epub 2011 Dec 7. Neurology. 2011. PMID: 22156988
Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.
Jarius S, Paul F, Franciotta D, de Seze J, Münch C, Salvetti M, Ruprecht K, Liebetrau M, Wandinger KP, Akman-Demir G, Melms A, Kristoferitsch W, Wildemann B. Jarius S, et al. Among authors: de seze j. Mult Scler. 2012 Aug;18(8):1135-43. doi: 10.1177/1352458511431728. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183934 Review.
Evaluation of new immunological targets in neuromyelitis optica.
Chanson JB, Paolini I, Collongues N, Alcaro MC, Blanc F, Barbetti F, Fleury M, Peroni E, Rovero P, Rudolf G, Lolli F, Trifilieff É, Papini AM, de Seze J. Chanson JB, et al. Among authors: de seze j. J Pept Sci. 2013 Jan;19(1):25-32. doi: 10.1002/psc.2470. Epub 2012 Nov 28. J Pept Sci. 2013. PMID: 23193094
Longitudinal follow-up of vision in a neuromyelitis optica cohort.
Bouyon M, Collongues N, Zéphir H, Ballonzoli L, Jeanjean L, Lebrun C, Chanson J, Blanc F, Fleury M, Outteryck O, Defoort S, Labauge P, Vermersch P, Speeg C, De Seze J. Bouyon M, et al. Among authors: de seze j. Mult Scler. 2013 Sep;19(10):1320-2. doi: 10.1177/1352458513476562. Epub 2013 Feb 14. Mult Scler. 2013. PMID: 23413296
523 results